Corvus Pharmaceuticals, Inc.
(NASDAQ : CRVS)

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.13%163.560.7%$1160.35m
PFEPfizer Inc. 0.19%36.550.9%$1138.06m
LLYEli Lilly & Co. 1.95%206.301.1%$934.48m
ABBVAbbVie, Inc. -0.34%110.881.9%$732.28m
BMYBristol-Myers Squibb Co. 0.61%64.571.0%$679.31m
MRKMerck & Co., Inc. -0.26%80.970.7%$677.96m
AZNAstraZeneca Plc 1.33%53.251.2%$669.74m
ARCTArcturus Therapeutics Holdings, Inc. 6.16%67.700.0%$229.98m
GRTSGritstone Oncology, Inc. 6.11%27.110.0%$211.05m
VTRSViatris, Inc. 0.69%17.430.0%$193.56m
RPRXRoyalty Pharma Plc 1.47%51.160.2%$174.27m
NVSNovartis AG 0.06%96.940.2%$174.04m
GSKGlaxoSmithKline Plc 1.54%38.360.2%$154.42m
SNYSanofi 0.10%49.690.2%$134.98m
RGENRepligen Corp. 1.11%219.326.9%$78.39m

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.